Shizawa T, Maeda K, Abe K, Ishii T, Kamitani T
Research and Development Center, Terumo Corp., Kanagawa, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):815-9. doi: 10.1007/pl00005122.
TMK688 (1-[[5'-(3"-methoxy-4"-ethoxycarbonyloxyphenyl)-2',4'-pentadien oyl] aminoethyl]-4-diphenylmethoxypiperidine) is being developed as an orally effective antiallergic drug having both 5-lipoxygenase inhibitory activity and anti-histamine activity (Shizawa et al. 1996; Tohda et al. 1997). The efficacy of TMK688 against allergic rhinitis was examined in passively sensitized guinea pigs. TMK688 inhibited the increase in intranasal resistance following antigen challenge at doses of 1 and 3.2 mg/kg p.o. The allergic nasal obstruction was also suppressed by 10 mg/kg i.v. of FPL-55712, a peptide leukotriene receptor antagonist, but not by 3.2 mg/kg i.v. pyrilamine, a histamine H1 receptor antagonist, or by 10 mg/kg p.o. of ketotifen, an anti-allergic drug having anti-histamine activity, suggesting that the nasal obstruction was caused by leukotrienes. Following antigen challenge, the intranasal release of leukotrienes B4 and C4, and histamine increased in passively sensitized guinea pigs. TMK688 tended to suppress the increase in immunoreactive leukotrienes B4 and C4 in the nasal lavage fluid at a dose of 1 mg/kg p.o., and significantly inhibited the increase at 3.2 mg/kg. The brilliant blue dye leakage following antigen challenge from the blood stream into the nasal cavities was significantly inhibited by not only TMK688 and FPL-55712 but also pyrilamine, suggesting that the allergic dye leakage was caused cooperatively by leukotrienes and histamine. However, ketotifen showed no significant suppression of the dye leakage even at 10 mg/kg p.o., although this drug inhibited the histamine-induced dye leakage at far lower doses (0.1 mg/kg p.o. or higher) in unsensitized guinea pigs. Therefore, histamine is not necessarily the major mediator of allergic dye leakage in our experiment. These findings demonstrate that TMK688 may be superior to antihistamines as a therapeutic agent for allergic rhinitis.
TMK688(1-[[5'-(3"-甲氧基-4"-乙氧基羰基氧苯基)-2',4'-戊二烯酰基]氨基乙基]-4-二苯基甲氧基哌啶)正在被开发为一种具有5-脂氧合酶抑制活性和抗组胺活性的口服有效抗变态反应药物(Shizawa等人,1996年;Tohda等人,1997年)。在被动致敏的豚鼠中检测了TMK688对变应性鼻炎的疗效。TMK688在1和3.2毫克/千克口服剂量下可抑制抗原激发后鼻内阻力的增加。10毫克/千克静脉注射肽白三烯受体拮抗剂FPL-55712也可抑制变应性鼻阻塞,但3.2毫克/千克静脉注射组胺H1受体拮抗剂吡苄明或10毫克/千克口服具有抗组胺活性的抗变态反应药物酮替芬则不能,这表明鼻阻塞是由白三烯引起的。抗原激发后,被动致敏豚鼠鼻内白三烯B4和C4以及组胺的释放增加。TMK688在1毫克/千克口服剂量下倾向于抑制鼻灌洗液中免疫反应性白三烯B4和C4的增加,在3.2毫克/千克时可显著抑制其增加。不仅TMK688和FPL-55712,而且吡苄明都可显著抑制抗原激发后从血流到鼻腔的亮蓝染料渗漏,这表明变应性染料渗漏是由白三烯和组胺共同引起的。然而,酮替芬即使在10毫克/千克口服剂量下也未显示出对染料渗漏的显著抑制作用,尽管该药物在未致敏豚鼠中以低得多的剂量(0.1毫克/千克口服或更高)即可抑制组胺诱导的染料渗漏。因此,在我们的实验中,组胺不一定是变应性染料渗漏的主要介质。这些发现表明,TMK688作为变应性鼻炎的治疗药物可能优于抗组胺药。